Enhancing Prostate Cancer Diagnosis with AI – Insights from the Uro-oncology Congress

Singapore, January 17, 2025 — Qritive participated in the International Congress on Frontiers in Urologic Oncology and Uropathology, held from January 10–12, 2025, in Bhubaneswar, Odisha, India. This international gathering brought together leading experts in uro-oncology and pathology to explore the latest advancements shaping the future of cancer diagnostics.

During the event, the Qritive team delivered a session titled “Augmenting Prostate Cancer Diagnosis with AI: Real-World Insights, Challenges & Solutions,” presenting the clinical impact of QAi Prostate Grade—an AI-powered solution designed to support pathologists in achieving faster, more accurate diagnoses and greater confidence in reporting.

The congress provided an excellent platform for engaging with the global pathology and uro-oncology community. Digital pathology and AI featured prominently throughout the program, underscoring their increasing relevance in improving diagnostic workflows and patient outcomes.

We thank the organizers for curating an insightful and well-attended event and look forward to furthering innovation in the field of uropathology.

About Qritive

Qritive, headquartered in Singapore with operations in the US and India, is transforming digital pathology through advanced AI-powered solutions that support cancer diagnosis and improve health outcomes.

By leveraging cutting-edge deep learning technology, Qritive supports pathologists in the interpretation of pathology assessments and enhances pathology workflows—enabling faster, more accurate diagnoses and reducing time to treatment.

Qritive is committed to empowering healthcare professionals around the world with tools that promote collaboration and high performance, regardless of complexity or distance.

Get in Touch

Want to learn more about our solutions or explore potential collaborations?

Visit www.qritive.com or contact us at info@qritive.com.